New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
|Poll|February 14, 2019
Mini Quiz: Supported Housing for Vulnerable Patients
Author(s)Sonya Gabrielian, MD, MPH
What factors are associated with loss of supported housing for chronically homeless patients with serious mental illnesss? Take the quiz and learn more.
Advertisement
What factors are associated with loss of supported housing?
What factors are associated with loss of supported housing?
Advertisement
Related to this article
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Presenting Our November 2026 Theme: Emergency Psychiatry
2
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
5